Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
- MeSH
- aldehyddehydrogenasa metabolismus MeSH
- buněčná diferenciace MeSH
- buněčné dělení MeSH
- buněčné jádro metabolismus MeSH
- buňky kostní dřeně cytologie účinky léků metabolismus MeSH
- časové faktory MeSH
- chemokin CCL4 MeSH
- cyklofosfamid analogy a deriváty metabolismus farmakologie MeSH
- cytokiny biosyntéza metabolismus MeSH
- hematopoetické kmenové buňky cytologie metabolismus MeSH
- hematopoéza účinky léků MeSH
- imunosupresiva farmakologie MeSH
- inhibitory syntézy proteinů farmakologie MeSH
- kmenové buňky účinky léků MeSH
- komplementární DNA metabolismus MeSH
- lymfocyty účinky léků MeSH
- makrofágové zánětlivé proteiny metabolismus MeSH
- membránové proteiny metabolismus MeSH
- messenger RNA metabolismus MeSH
- myši inbrední BALB C MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- slezina cytologie účinky léků fyziologie MeSH
- thymidin chemie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- aldehyddehydrogenasa MeSH
- chemokin CCL4 MeSH
- cyklofosfamid MeSH
- cytokiny MeSH
- flt3 ligand protein MeSH Prohlížeč
- imunosupresiva MeSH
- inhibitory syntézy proteinů MeSH
- komplementární DNA MeSH
- mafosfamide MeSH Prohlížeč
- makrofágové zánětlivé proteiny MeSH
- membránové proteiny MeSH
- messenger RNA MeSH
- thymidin MeSH
Sublethal cyclophosphamide treatment induces unique regeneration patterns in bone marrow and the spleen of a mouse. Colony-forming units spleen (CFU-S)(day 8), CFU-granulocyte-macrophage (GM), nucleated cell counts, and their differentials in bone marrow, spleen, and peripheral blood were determined in mice treated with a single dose of cyclophosphamide. To study further the mechanisms underlying the unique patterns of hematopoietic regeneration after cyclophosphamide, mRNA levels for stem cell factor (SCF), Flt-3 ligand, and macrophage inflammatory factor (MIP)-1 alpha cytokines were determined in bone marrow and spleen. Granulocyte precursor cells were less depleted by cyclophosphamide compared to erythroid nucleated cells and lymphocytes both in bone marrow and spleen. Rapid expansion of granulopoietic cells increased the granulocytic/erythroid ratio significantly during regeneration. CFU-S in the bone marrow and the spleen showed different sensitivity in vivo but not in vitro to cyclophosphamide; CFU-GM were equisensitive in both sites. In bone marrow, an initial fast recovery of CFU-S and CFU-GM on days 2 to 3 was followed by a secondary deep decline in their numbers occurring between days 5 and 7. This decline was accompanied with a depression of CFU-S proliferation and with significantly increased CFU-S numbers in the peripheral blood. In the spleen, absolute CFU-S and CFU-GM numbers were increased several-fold at this time. Seven days after cyclophosphamide, the spleen contained 69% of the total body CFU-S compared to 4% in controls. Splenectomy did not abolish the secondary disease of CFU-S in the bone marrow, but it led to a marked elevation of circulating leukocytes and CFU-S. There was an eight-fold increase in the SCF mRNA level in the bone marrow 2 days after cyclophosphamide, corresponding with a high proliferation rate of CFU-S. No significant changes in mRNAs for Flt-3 ligand and MIP-1 alpha have been found. This in-depth analysis of murine hematopoietic responses to cyclophosphamide provides evidence for the complexity of the involved local and systemic regulations. This represents a significant challenge to experimental hematology, which could now be tackled with methods allowing the study of changes in the gene expression during cyclophosphamide-induced hematopoietic damage.
Citace poskytuje Crossref.org